-transparent.png){kind=logo}
We determined the serum levels of the creatine kinase B subunit (CK-B) by an enzyme immunoassay method in patients with renal cell carcinoma (RCC) and benign renal diseases. Eighteen of 76 patients with RCC (24%) had elevated serum CK-B levels. The positive rates were 29% in stage I, 13% in stage II, 15% in stage III, and 27% in stage IV. In all 9 patients whose serum CK-B levels were serially measured and had been elevated before operation, the CK-B levels were reduced to the normal range after nephrectomy. These findings indicate that serum CK-B is a useful biomarker for monitoring the clinical course for a limited number of RCC patients, but is not a marker for diagnosis and staging. Concentrations of CK-B in RCC tissues were significantly lower than those of normal kidney. A high rate of cell turnover in tumor tissues might entail the higher level of serum CK-B in patients with RCC.
M Takashi, and
Y Zhu, and
S Hasegawa, and
K Kato
December 1979,
Clinical biochemistry,
M Takashi, and
Y Zhu, and
S Hasegawa, and
K Kato
January 1985,
Journal of neurology,
M Takashi, and
Y Zhu, and
S Hasegawa, and
K Kato
February 1982,
Clinical chemistry,
M Takashi, and
Y Zhu, and
S Hasegawa, and
K Kato
July 1979,
Clinical chemistry,
M Takashi, and
Y Zhu, and
S Hasegawa, and
K Kato
January 1984,
Clinical chemistry,
M Takashi, and
Y Zhu, and
S Hasegawa, and
K Kato
May 1980,
British heart journal,
M Takashi, and
Y Zhu, and
S Hasegawa, and
K Kato
May 1987,
Mayo Clinic proceedings,
M Takashi, and
Y Zhu, and
S Hasegawa, and
K Kato
January 1985,
Acta neurologica Scandinavica,
M Takashi, and
Y Zhu, and
S Hasegawa, and
K Kato
February 1986,
European journal of clinical investigation,
M Takashi, and
Y Zhu, and
S Hasegawa, and
K Kato
April 1982,
Clinical chemistry,
